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THE IMPACT OF METHYLENETETRAHYDROFOLATE REDUCTASE C677T
GENE POLYMORPHISM ON ENGRAFTMENT AFTER ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANTATION IN PATIENTS RECEIVING METH-
OTREXATE IN GRAFT VERSUS HOST DISEASE PROPHYLAXIS
Arat, M.1, Soydan, E.1, Topcuoglu, P.1, Ozcan, M.1, Arslan, O.1,
Gurman, G.1, Ilhan, O.1 1Ankara University Medical School, Hema-
tology Department, BMT Unit, Ankara, Turkey.
Methotrexate (MTX) is an antifolate chemotherapeutic drug and
is used to prevent graft versus host disease (GVHD) in allogeneic
hemapoietic cell transplantation (AHCT). The effectiveness of
MTX is largely attributable to its role of MTHR and its gene
polymorphism is a common (10-12% homozygote and 40% het-
erozygote) variation in the population. Depending on to this ﬁnd-
ing, we investigated whether MTHFR C677T gene polymorphism
has any affect on engraftment kinetics of patients undergoing
ASCT to whom MTX is given for GVHD prophylaxis. We ret-
rospectively analyzed our cohort of 82 allogeneic stem cell recip-
ients whose MTHFR gene polymorphism of C677T region was
analyzed by RT-PCR for the pretransplant evaluation of hereditary
thrombophilia. The patient’s median age was 31 (range, 14-50)
years, with a M/F: 50/32 and diagnosis; 35 AML, 26 CML, 12 ALL
and 9 other. Nearly all of the patients were given standard condi-
tioning regimen consisting of BUCY or TBICY. All of the patients
received cyclosporine A and short term MTX for GVHD prophy-
laxis. Stem cell source was bone marrow (BM) in 23 and peripheral
blood (PB) in 59 of the patients. MTHFR gene polymorphism was
detected in 32 (39%) of all patients, and 90% were heterozygotes
(MTHFR HeZ). When we compared the engraftment kinetics,
granulocyte engraftment was found to be late in MTHFR HeZ
group (neutrophil 1000 median 19 vs 17 days; P  .01) but not
different for neutrophil 500 and platelet engraftment. We have
observed that MTHFR gene polymorphism had a prominent effect
on BM recipients, as both neutrophil 500 and 1000 and also
platelet engraftments were affected (granulocyte 500 median 21 vs
15 P .005; granulocyte 1000 median 22.5 vs 17 P .0001 and plt
20 median 27 vs 21 P  .03) signiﬁcantly. On the contrary, there
was no difference in the PB group. The number of MNC and
CD34 cells were similar in patients with and without gene poly-
morphism both in BM and PG group. When we compare the side
effects of MTX such as nausea and vomiting, diarrhea, mucositis,
there was no difference in acute GVHD incidence. Our knowledge
on epigenetic data will help us on tailoring the chemotherapy
regimen for conditioning and GvHD prophylaxis in transplant
recipients. Our data on a limited patient size suggest that the
presence of MTHFR HeZ may have an impact on allo HCT
recipients engraftment kinetics while using MTX for GVHD pro-
phylaxis and BM as stem cell source.
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SIROLIMUS AND TACROLIMUS WITHOUT METHOTREXATE AS GRAFT-
VS.-HOST DISEASE PROPHYLAXIS AFTER MATCHED, UNRELATED PE-
RIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT): EXCEL-
LENT GVHD CONTROL WITH LOW TRANSPLANT-RELATED MORBIDITY
AND MORTALITY
Cutler, C.1, Li, S.2, Kim, H.T.2, Macdonell, R.1, Ho, V.1, Alyea, E.1,
Lee, S.J.1, Soiffer, R.1, Antin, J.H.1 1Medical Oncology, Dana-Farber
Cancer Institute, Boston, MA; 2Biostatistics and Computational Biology,
Dana-Farber Cancer Institute, Boston, MA.
We have previously demonstrated that the combination of siroli-
mus (rapamycin, Rap), tacrolimus (Tac) and low-dose methotrex-
ate (Mtx) is effective GVHD prophylaxis in URD transplantation,
and the combination of Rap and Tac alone is effective in MRD
transplantation. Since Mtx is associated with transplant-related
toxicity and delayed engraftment, we hypothesized that Rap and
Tac, without Mtx, would provide effective GVHD prophylaxis in
URD transplantation while minimizing transplant-related morbid-
ity and mortality. Methods: 30 subjects underwent PBSCT from
6/6 HLA-matched unrelated donors after Cy/TBI conditioning.
GVHD prophylaxis consisted of Rap (target serum level 3-12
ng/ml) and Tac (target serum level 5-10 ng/ml). G-CSF (5 g/kg)
was administered from day 12 until engraftment, if needed.
Results: The median age of subjects was 44 years (range 22-54).
Diagnoses were AML (13), CML (6), NHL (4), MDS (3), ALL (2),
MPD (1) and HD (1). The median times to neutrophil (	500/L)
and platelet engraftment (	20000/L and 	100000/L) were
13.5 (range 11-14), 12 (range 9-25), and 17 (range 12-101) days,
respectively. Two patients did not become platelet transfusion
independent. All 30 patients survived to ﬁrst hospital discharge, at
a median of 19 days from day 0 (range 14-55). Gr. II-IV acute
GVHD occurred in 5 patients (16.7%) with only one case of Gr.
IV acute GVHD (3.3%). Transplant-related morbidity was low,
without any cases of IPS/DAH. Two subjects developed VOD and
one subject developed thrombotic microangiopathy. Reactivation
of HHV-6 with limbic encephalitis was noted in 2 patients. 13 of
25 evaluable patients developed chronic GVHD. Five patients
relapsed, one of whom achieved a durable complete remission after
immunosuppression withdrawal and DLI. Causes of death include
relapse (3), VOD (1), and relapse with VOD and hepatic GVHD
(1). The median follow-up is 230 days (range 46-608). Treatment-
related mortality at 100 days is 3.3%. Relapse-free and overall
survival at day 100 are both 93.1%, and at 1 year are 78.1% and
80.9%, respectively. Conclusions: Rap and Tac without Mtx is
effective for GVHD prophylaxis after matched URD PBSCT,
leading to acute GVHD in 16.7% of treated patients, which is
similar to our experience using Rap and Tac in MRD transplan-
tation. Furthermore, the omission of Mtx is associated with min-
imal transplant-related morbidity and mortality at 100 days. This
combination is worthy of broader study in unrelated donor trans-
plantation.
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MEASURING MULTIPLE SYMPTOMS AND INFLAMMATORY CYTOKINES
RELATED TO ACUTE GVHD IN AML/MDS PATIENTS UNDERGOING AL-
LOGENEIC BMT
Giralt, S.1, Cleeland, C.S.1, Reuben, J.1, Lee, B.-N.1, Williams, L.A.1,
Mobley, G.1, Wang, X.S.1 1University of Texas M. D. Anderson Cancer
Center, Houston, TX.
The objective of this study was to prospectively assess the rela-
tionship between symptom severity and changes in inﬂammatory
cytokines around the time of diagnosis of acute GVHD in AML/
MDS patients during the ﬁrst 100 days of allo-BMT. Methods:
Weekly symptom assessment with the M. D. Anderson Symptom
Inventory was done for 30 patients for the ﬁrst 100 days following
BMT. A panel of inﬂammatory cytokines (IL-1ra, IL-6, IL-8,
IL-10, IL-12, TNF-
) was assayed at multiple time points (pre-
BMT, conditioning, day of BMT, BMT day 1, nadir, BMT days
8, 14, 21, 28, 60, and 90-100, also days 1, 3, 5, 10 and
15 of diagnosis of acute GVHD for the 26 patients who developed
it). Results: Of the 26 patients who developed acute GVHD, 69%
had grade 1 GVHD, 27% had grade 2, and 4% had grade 3. 42%
were treated systemically with a dose of 2 mg/kg of steroids, and
31% were treated with topical steroids alone. Non-speciﬁc symp-
toms experienced by these patients reached their highest levels
shortly before the day of diagnosis of acute GVHD. Immediate
symptom reduction occurred after diagnosis of acute GVHD and
was most likely caused by administration of steroids. IL-8 was
signiﬁcantly correlated with some symptoms before and after di-
agnosis of acute GVHD (Table 1). Conclusion: During develop-
ment of GVHD in the acute phase of allo-BMT, there was an
observed relationship of severity of certain symptoms and in-
creased or decreased inﬂammatory cytokine levels in this pilot
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